NVCR logo

NVCR

NovoCure Limited

$11.95
+$0.49(+4.28%)
43
Overall
60
Value
27
Tech
--
Quality
Market Cap
$1.28B
Volume
1.99M
52W Range
$10.70 - $34.13
Target Price
$25.06

Company Overview

Mkt Cap$1.28BPrice$11.95
Volume1.99MChange+4.28%
P/E Ratio-7.6Open$11.40
Revenue$605.2MPrev Close$11.46
Net Income$-168.6M52W Range$10.70 - $34.13
Div YieldN/ATarget$25.06
Overall43Value60
Quality--Technical27

No chart data available

About NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Latest News

NovoCure’s Mixed Q3: Growth Amid Challenges

NovoCure Ltd. (($NVCR)) has held its Q3 earnings call. Read on for the main highlights of the call. NovoCure Ltd. recently held its third-quarter e...

TipRanks Auto-Generated Newsdesk23 days ago

Novocure Ltd. Reports Q3 2025 Financial Results

TipRanks Auto-Generated Newsdesk24 days ago

NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment

TipRanks Clinical-Trials-Auto-Generated Newsdeska month ago

NovoCure’s LUNAR-4 Study: A New Horizon in Lung Cancer Treatment

TipRanks Clinical-Trials-Auto-Generated Newsdeska month ago
ABCD
1SymbolPriceChangeVol
2NVCR$11.95+4.3%1.99M
3
4
5
6

Get NovoCure Limited Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.